IFP Advisors Inc Purchases 176,649 Shares of Abbott Laboratories $ABT

Key Points

• IFP Advisors increased its Abbott Laboratories position by 307.1% in the second quarter, acquiring 176,649 additional shares for a total holding of 234,173 shares valued at approximately $21.25 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $118.67. Recent ratings include several “Outperform” and “Overweight” recommendations, though some firms lowered their price targets.
• Abbott reported quarterly earnings of $1.31 per share on $12.59 billion in revenue, beating estimates and marking 13% year-over-year revenue growth. The company pays a quarterly dividend of $0.63, equivalent to a 2.2% annual yield.

IFP Advisors Inc boosted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 307.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 234,173 shares of the healthcare product maker's stock after acquiring an additional 176,649 shares during the period. IFP Advisors Inc's holdings in Abbott Laboratories were worth $21,249,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. FLC Capital Advisors raised its stake in shares of Abbott Laboratories by 3.4% during the second quarter. FLC Capital Advisors now owns 4,098 shares of the healthcare product maker's stock valued at $372,000 after acquiring an additional 135 shares during the last quarter. Aull & Monroe Investment Management Corp grew its stake in shares of Abbott Laboratories by 4.9% in the second quarter. Aull & Monroe Investment Management Corp now owns 10,606 shares of the healthcare product maker's stock worth $962,000 after purchasing an additional 500 shares during the last quarter. Owl Creek Wealth Partners LLC increased its holdings in Abbott Laboratories by 44.8% during the 2nd quarter. Owl Creek Wealth Partners LLC now owns 2,571 shares of the healthcare product maker's stock valued at $233,000 after purchasing an additional 795 shares during the period. Merit Financial Group LLC raised its position in Abbott Laboratories by 22.0% during the 2nd quarter. Merit Financial Group LLC now owns 77,836 shares of the healthcare product maker's stock valued at $7,063,000 after purchasing an additional 14,031 shares during the last quarter. Finally, C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors lifted its holdings in Abbott Laboratories by 0.6% in the 2nd quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors now owns 19,687 shares of the healthcare product maker's stock worth $1,786,000 after buying an additional 114 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ABT. Royal Bank Of Canada reiterated an "outperform" rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Robert W. Baird started coverage on Abbott Laboratories in a research note on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target for the company. Piper Sandler reiterated an "overweight" rating and issued a $118.00 price target (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating on the stock in a research report on Tuesday, April 21st. Finally, Bank of America decreased their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $118.67.

Abbott Laboratories Trading Up 2.3%

Abbott Laboratories stock opened at $112.92 on Wednesday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a market capitalization of $195.39 billion, a price-to-earnings ratio of 36.54, a price-to-earnings-growth ratio of 2.15 and a beta of 0.59. The business's fifty day simple moving average is $98.51 and its two-hundred day simple moving average is $99.84. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company's revenue was up 13.0% on a year-over-year basis. During the same period last year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. Abbott Laboratories's payout ratio is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source